Venture capital fund
Venture firm backing early-stage healthcare and medtech startups
Every published round Synthesis Capital took part in, and every parcel of existing shares it bought off another holder. Deals we hold but haven't published yet are not counted.
Companies Synthesis Capital has backed in a published round, and companies whose existing shares it bought off another holder.
| Company | What it does | First invested | Rounds | Led |
|---|---|---|---|---|
| No portfolio companies recorded yet. | ||||
Fund closes reported for Synthesis Capital, as distinct from the investments it has made.
Companies Synthesis Capital has backed that another company then bought. An exit for the holding, not a deal Synthesis Capital did.
| Name | Role | Sources |
|---|---|---|
| Dr Buzz Palmer | Partner | Startup Daily, Synthesis Capital team page |
Stories naming Synthesis Capital. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
MedTech Actuator alumni are behind Synthesis Capital, a new venture fund courting investors for up to $100m to back young health technology companies across Australia and the Asia-Pacific.
Weekly agrifoodtech roundup: raises by Everytable, Bluu Seafood, Hyfe, eFishery, eAgronom and Stacked Farm; fund closes by Omnivore, Innova Memphis and Joyful Ventures; Meituan buys Light Year; Vindara sold; Honest AgTech bankrupt.